Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Rajni Kant; Gaurav Dwivedi; Kamran Zaman; Rima R Sahay; Gajanan Sapkal; Himanshu Kaushal; Dimpal A Nyayanit; Pragya D Yadav; Gururaj Deshpande; Rajeev Singh; Sandeep Chaowdhary; Nivedita Gupta; Sanjay Kumar; Priya Abraham; Samiran Panda; Balram Bhargava

doi:10.1093/jtm/taab166

letter

. 2021 Oct 15:taab166. doi: 10.1093/jtm/taab166

Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Rajni Kant ¹, Gaurav Dwivedi ², Kamran Zaman ³, Rima R Sahay ⁴, Gajanan Sapkal ⁵, Himanshu Kaushal ⁶, Dimpal A Nyayanit ⁷, Pragya D Yadav ^8,^✉, Gururaj Deshpande ⁹, Rajeev Singh ¹⁰, Sandeep Chaowdhary ¹¹, Nivedita Gupta ¹², Sanjay Kumar ¹³, Priya Abraham ¹⁴, Samiran Panda ¹⁵, Balram Bhargava ¹⁶

¹Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India

²Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India

³Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India

⁴Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India

⁵Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India

⁶Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India

⁷Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India

⁸Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India

⁹Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India

¹⁰Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India

¹¹Chief Medical Officer, Community Health Centre, Siddarthnagar, Uttar Pradesh, 272207, India

¹²Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India

¹³Command Hospital (Southern Command), Armed Forces Medical College, Pune, Maharashtra, 411040, India

¹⁴Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India

¹⁵Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India

¹⁶Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India

^✉

To whom correspondence should be addressed. Dr Pragya D. Yadav, Scientist ‘E’ and Group Leader, Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra, 411021, India. Phone: +9120-26006111; Fax No. 91-20-26122669; Email: hellopragya22@gmail.com

PMCID: PMC8524638 PMID: 34652440

Abstract

The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.

Keywords: Immunogenecity, Heterologous regime, Covishield, Covaxin, SARS-CoV-2

PERMALINK

Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Rajni Kant, Ph.D

Gaurav Dwivedi, Ph.D

Kamran Zaman, MD

Rima R Sahay, MD

Gajanan Sapkal, Ph.D

Himanshu Kaushal, Ph.D

Dimpal A Nyayanit, Ph.D

Pragya D Yadav, Ph.D

Gururaj Deshpande, Ph.D

Rajeev Singh, Ph.D

Sandeep Chaowdhary, Ph.D

Nivedita Gupta, Ph.D

Sanjay Kumar, MCh

Priya Abraham, Ph.D

Samiran Panda, MD, DTM&H

Balram Bhargava, DM

Abstract

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Rajni Kant, Ph.D

Gaurav Dwivedi, Ph.D

Kamran Zaman, MD

Rima R Sahay, MD

Gajanan Sapkal, Ph.D

Himanshu Kaushal, Ph.D

Dimpal A Nyayanit, Ph.D

Pragya D Yadav, Ph.D

Gururaj Deshpande, Ph.D

Rajeev Singh, Ph.D

Sandeep Chaowdhary, Ph.D

Nivedita Gupta, Ph.D

Sanjay Kumar, MCh

Priya Abraham, Ph.D

Samiran Panda, MD, DTM&H

Balram Bhargava, DM

Abstract

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases